AfamelanotideSpecialist prescription medicine
Afamelanotide influences pigment production and has been developed for erythropoietic protoporphyria, a rare condition in which light exposure can cause severe pain.
What is Afamelanotide?
Afamelanotide is a melanocortin-related medicine developed for erythropoietic protoporphyria, or EPP, a rare condition in which light exposure can cause severe pain. The clinical preparation is a slow-release implant.
How it works
It promotes eumelanin pigment production through melanocortin signalling. The clinical goal is greater light tolerance in EPP, rather than simply a darker cosmetic tan.
Effects studied
Pain-free light exposure in EPP
Controlled implant studies assess pain-free time in sunlight and related symptoms in adults with EPP. That evidence does not establish safe unrestricted ultraviolet exposure or equivalence of tanning injections. 1
Evidence: Controlled trials in a defined rare disease
What does the evidence show?
The archive includes controlled trials of a regulated implant in adults with EPP. Those results do not establish the safety of online tanning injections.
The problem the medicine addresses
For someone with erythropoietic protoporphyria, ordinary daylight can impose major restrictions. Afamelanotide mimics a melanocortin signal that encourages production of eumelanin, a skin pigment. The idea is to improve tolerance to light in that specific biological setting, rather than to remove every consequence of ultraviolet exposure.
Why the implant matters
The clinical preparation is a slowly releasing implant placed under the skin. The findings apply to that formulation, the clinical supervision and the population studied. Although Melanotan I is associated with the same molecular identity, a vial marketed under that name is not interchangeable with the studied implant. 1
What researchers measured
Pain-free time in sunlight and related symptoms are more directly relevant to EPP than simply measuring a darker skin colour. The archive’s trial references address that clinical goal. They do not establish that a cosmetic tan makes unrestricted sun exposure safe or that an unverified preparation shares the same risk profile.
Monitoring still matters
Changes in pigment can alter the appearance of existing moles, so skin surveillance remains important. Implant-site reactions and nausea also feature in product information. The European regulator’s entry and current prescribing material should guide a product-specific review, rather than a generic peptide-market description. 3
Safety & status
Pigment changes, changes in existing moles, implant-site reactions and nausea are relevant. Skin surveillance remains important. 3
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Is Melanotan I the same clinical product?
The name is associated with the same molecule, but an online vial is not equivalent to the studied slow-release implant.
Does it replace sun protection?
A pigmentation response does not remove every consequence of ultraviolet exposure or make unlimited exposure safe.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Afamelanotide: www.accessdata.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Afamelanotide: www.mcgill.ca reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Afamelanotide: www.ema.europa.eu reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Afamelanotide: www.biospace.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.